

1. Record Nr.	UNINA9910639877503321
Autore	Macheras P (Panos)
Titolo	Revising oral pharmacokinetics, bioavailability and bioequivalence based on the finite absorption time concept / / Panos Macheras and Athanasios A. Tsekouras
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2023] ©2023
ISBN	3-031-20025-X
Descrizione fisica	1 online resource (137 pages)
Disciplina	615.7
Soggetti	Drugs - Bioavailability Drugs - Absorption and adsorption Oral medication Pharmacokinetics Biological Availability Biopharmaceutics Drug Therapy
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	Intro -- Foreword -- Preface -- Contents -- Part I: Oral Pharmacokinetics -- Chapter 1: From Bateman (1910) to Dost (1953) -- 1.1 Harry Bateman: First-Order Kinetics in Physics (1910) -- 1.2 Friedrich Hartmut Dost: First-Order Kinetics in Pharmacokinetics (1953) -- 1.3 Simulations Based on Bateman's Equation -- 1.4 The Fundamental Metrics of Bioavailability/Bioequivalence Studies -- References -- Chapter 2: The Unphysical Hypothesis of Infinite Absorption Time -- 2.1 The Biopharmaceutical-Pharmacokinetic Basis of the Bateman Equation -- 2.2 State of the Art in Oral Drug Absorption -- 2.2.1 The PK Route -- 2.2.1.1 Questioning the Absorption Rate Constant, k_a -- 2.2.1.2 PBPK Models -- 2.2.2 The Bioph Route -- 2.2.3 The Absorption Rate Constant (k_a) Links the Bioph and PK Routes -- 2.3 The Unphysical Hypothesis of Infinite Absorption Time -- 2.4 Concluding Remarks -- References -- Chapter 3: The Finite Absorption Time (FAT) Concept -- 3.1 Sink Conditions Imply Zero-Order Kinetics

-- 3.2 Finite Absorption Time -- 3.2.1 Modeling Work: Combining BCS with Absorption Kinetics -- 3.3 Simulations -- 3.3.1 Physiological Considerations -- 3.3.2 Drug Absorption: Reconsidered in Terms of the FAT -- 3.4 Fits to Data -- 3.5 Epilogue -- References -- Chapter 4: The Rise of Physiologically Based Finite Time Pharmacokinetic (PBFTP) Models -- 4.1 Models -- 4.2 Simulations -- 4.3 Fits to Data -- 4.4 Toward a Biopharmaceutics-Pharmacokinetic Classification System (BPCS) -- 4.5 Future Work -- References -- Part II: Bioavailability-Bioequivalence -- Chapter 5: History of the Bioavailability-Bioequivalence Concepts -- 5.1 Early 1900s-Today: Variations in Response to Xenobiotics -- 5.2 1950s: The First Pharmacokinetic-Pharmacodynamic Correlations -- 5.3 1953: The Publication of Dost's First Pharmacokinetics Book in History. 5.4 1960s: Biopharmaceutics-Pharmacokinetics at Its Infancy -- 5.5 "The Bioavailability Problem" -- 5.6 The Introduction of an Official Dissolution Test in 1970 (USP Apparatus 1) -- 5.7 FDA (1977): Bioavailability Is the Rate and Extent to Which the Active Ingredient or Active Moiety Is Absorbed from a Drug... -- 5.7.1 A Persisting Problem: The Use of C_{max} as a Metric of Rate of Absorption -- References -- Chapter 6: Therapeutic Equivalence Based on Bioequivalence Studies -- 6.1 From 1977 to Now: Bioequivalence Criteria and Issues -- 6.2 Highly Variable Drugs or Drug Products (HVD) -- 6.3 Epilogue -- References -- Chapter 7: Bioavailability Under the Prism of Finite Absorption Time -- 7.1 The Columbus' Egg: Drug Absorption Takes Place Under Sink Conditions for Finite Time -- 7.2 A Paradigm Shift in Oral Drug Absorption -- 7.3 Bioavailability Parameters Under the Prism of Finite Absorption Time Concept -- 7.3.1 One Compartment Model with One Constant Input Rate Operating for Time -- 7.3.2 One Compartment Model with More than One Constant Input Rates Operating for a Total Time -- 7.3.3 One Compartment Model with First-Order Absorption Lasting for Time and First-Order Elimination -- 7.4 Extent (Exposure) and Rate Metrics -- 7.5 Extent and Rate of Absorption Metrics Under the Prism of Finite Absorption Time (FAT) -- 7.6 Scientific-Regulatory Implications -- 7.7 Toward the Unthinkable: Estimation of Absolute Bioavailability from Oral Data Exclusively -- References -- Chapter 8: Bioequivalence Under the Prism of Finite Absorption Time -- 8.1 Reconsidering Digoxin Bioavailability/Bioequivalence Studies in the Light of Finite Absorption Time Concept -- 8.2 Is the Proper Metric for Drug's Extent of Absorption -- 8.3 Toward the Revision of Bioequivalence Assessment -- 8.4 Does FDA's Bioavailability Definition of 1977 Require Reconsideration?.
References.
